Your browser doesn't support javascript.
loading
Prognostic Role of TAPSE to PASP Ratio in Patients Undergoing MitraClip Procedure.
Trejo-Velasco, Blanca; Estevez-Loureiro, Rodrigo; Carrasco-Chinchilla, Fernando; Fernández-Vázquez, Felipe; Arzamendi, Dabit; Pan, Manuel; Pascual, Isaac; Nombela-Franco, Luis; Amat-Santos, Ignacio J; Freixa, Xavier; Hernández-Antolín, Rosa Ana; Trillo-Nouche, Ramiro; Andraka Ikazuriaga, Leire; López-Mínguez, José R; Sanmiguel Cervera, Dario; Sanchis, Juan; Diez-Gil, José Luis; Ruiz-Quevedo, Valeriano; Urbano-Carrillo, Cristóbal; Becerra-Muñoz, Víctor Manuel; Benito-González, Tomás; Li, Chi Hion; Mesa, Dolores; Avanzas, Pablo; Armijo, Germán; Serrador-Frutos, Ana María; Sanchis, Laura; Lobán, Covadonga Fernández-Golfín; Cid-Álvarez, Belén; Hernández-García, José María; Garrote-Coloma, Carmen; Fernández-Peregrina, Estefanía; Romero, Miguel; León Arguero, Víctor; Cruz-González, Ignacio.
Afiliação
  • Trejo-Velasco B; Cardiology Department, University Hospital of Salamanca, Biomedical Research Institute of Salamanca (IBSAL), 37007 Salamanca, Spain.
  • Estevez-Loureiro R; Cardiology Department, Alvaro Cunqueiro University Hospital, 36213 Vigo, Spain.
  • Carrasco-Chinchilla F; Cardiology Department, Virgen de la Victoria University Hospital, Biomedical Research Institute of Málaga, 29010 Málaga, Spain.
  • Fernández-Vázquez F; Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), 28029 Madrid, Spain.
  • Arzamendi D; Cardiology Department, University Hospital of Leon, 24071 Leon, Spain.
  • Pan M; Cardiology Department, University Hospital Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  • Pascual I; Cardiology Department, University Hospital Reina Sofia, University of Cordoba and Maimonides Institute for Biomedical Research (IMIBIC), 14004 Córdoba, Spain.
  • Nombela-Franco L; Heart Area, Asturias Central University Hospital, University of Oviedo, Health Research Institute, 33011 Oviedo, Spain.
  • Amat-Santos IJ; Cardiovascular Institute, Hospital Clínico San Carlos, Health Research Institute San Carlos (IdISSC), 28040 Madrid, Spain.
  • Freixa X; Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), 28029 Madrid, Spain.
  • Hernández-Antolín RA; Cardiology Department, Clinic University Hospital of Valladolid, Heart Sciences Institute, 47003 Valladolid, Spain.
  • Trillo-Nouche R; Cardiology Department, Clínic University Hospital of Barcelona, University of Barcelona, Biomedical Research Institute August Pi i Sunyer (IDIBAPS), 08041 Barcelona, Spain.
  • Andraka Ikazuriaga L; Cardiology Department, Ramon y Cajal University Hospital, 28034 Madrid, Spain.
  • López-Mínguez JR; Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), 28029 Madrid, Spain.
  • Sanmiguel Cervera D; Cardiology Department, Clinical University Hospital of Santiago, 15706 Santiago de Compostela, Spain.
  • Sanchis J; Cardiology Department, University Hospital of Basurto, 48013 Bilbao, Spain.
  • Diez-Gil JL; Cardiology Department, University Hospital of Badajoz, 06080 Badajoz, Spain.
  • Ruiz-Quevedo V; Cardiology Department, General University Hospital of Valencia, 46014 Valencia, Spain.
  • Urbano-Carrillo C; Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), 28029 Madrid, Spain.
  • Becerra-Muñoz VM; Cardiology Department, University Clinic Hospital of Valencia, University of Valencia, 46010 Valencia, Spain.
  • Benito-González T; Cardiology Department, University & Polytechnical Hospital La Fe, 46026 Valencia, Spain.
  • Li CH; Cardiology Department, University Hospital of Navarra, 31008 Pamplona, Spain.
  • Mesa D; Cardiology Department, Regional University Hospital of Málaga, 29010 Málaga, Spain.
  • Avanzas P; Cardiology Department, Virgen de la Victoria University Hospital, Biomedical Research Institute of Málaga, 29010 Málaga, Spain.
  • Armijo G; Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), 28029 Madrid, Spain.
  • Serrador-Frutos AM; Cardiology Department, University Hospital of Leon, 24071 Leon, Spain.
  • Sanchis L; Cardiology Department, University Hospital Santa Creu i Sant Pau, 08041 Barcelona, Spain.
  • Lobán CF; Cardiology Department, University Hospital Reina Sofia, University of Cordoba and Maimonides Institute for Biomedical Research (IMIBIC), 14004 Córdoba, Spain.
  • Cid-Álvarez B; Heart Area, Asturias Central University Hospital, University of Oviedo, Health Research Institute, 33011 Oviedo, Spain.
  • Hernández-García JM; Cardiovascular Institute, Hospital Clínico San Carlos, Health Research Institute San Carlos (IdISSC), 28040 Madrid, Spain.
  • Garrote-Coloma C; Cardiology Department, Clinic University Hospital of Valladolid, Heart Sciences Institute, 47003 Valladolid, Spain.
  • Fernández-Peregrina E; Cardiology Department, Clínic University Hospital of Barcelona, University of Barcelona, Biomedical Research Institute August Pi i Sunyer (IDIBAPS), 08041 Barcelona, Spain.
  • Romero M; Cardiology Department, Ramon y Cajal University Hospital, 28034 Madrid, Spain.
  • León Arguero V; Biomedical Research Networking Center on Cardiovascular Diseases (CIBERCV), 28029 Madrid, Spain.
  • Cruz-González I; Cardiology Department, Clinical University Hospital of Santiago, 15706 Santiago de Compostela, Spain.
J Clin Med ; 10(5)2021 Mar 02.
Article em En | MEDLINE | ID: mdl-33801311
BACKGROUND: Transcatheter mitral valve repair (TMVR) is an effective therapy for high-risk patients with severe mitral regurgitation (MR) but heart failure (HF) readmissions and death remain substantial on mid-term follow-up. Recently, right ventricular (RV) to pulmonary arterial (PA) coupling has emerged as a relevant prognostic predictor in HF. In this study, we aimed to assess the prognostic value of tricuspid annular plane systolic excursion (TAPSE) to PA systolic pressure (PASP) ratio as a non-invasive measure of RV-to-PA coupling in patients undergoing TMVR with MitraClip (Abbott, CA, USA). METHODS: Multicentre registry including 228 consecutive patients that underwent successful TMVR with MitraClip. The sample was divided in two groups according to TAPSE/PASP median value: 0.35. The primary combined endpoint encompassed HF readmissions and all-cause mortality. RESULTS: Mean age was 72.5 ± 11.5 years and 154 (67.5%) patients were male. HF readmissions and all-cause mortality were more frequent in patients with TAPSE/PASP ≤ 0.35: Log-Rank 8.844, p = 0.003. On Cox regression, TAPSE/PASP emerged as a prognostic predictor of the primary combined endpoint, together with STS-Score. TAPSE/PASP was a better prognostic predictor than either TAPSE or PASP separately. CONCLUSIONS: TAPSE/PASP ratio appears as a novel prognostic predictor in patients undergoing MitraClip implantation that might improve risk stratification and candidate selection.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article